Double-Blind, Randomised, Placebo-Controlled Multicentre Phase III Clinical Study Followed by Open-Label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD.
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2016
At a glance
- Drugs Budesonide (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms BUM-5
- Sponsors Dr Falk Pharma
- 20 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 09 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.